Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-390.98	-372.18	-444.04	-395.89	-342.25
Depreciation & Amortization	47.32	48.07	33.13	21.14	13.98
Stock-Based Compensation	61.58	109.63	62.63	84.02	69.77
Other Adjustments	3.94	-11.48	-7.01	0.87	6.01
Change in Receivables	-13.11	-69.19	-0.15	-	-
Changes in Inventories	-14.21	-44.38	-	-	-
Changes in Accounts Payable	-6.66	-7.84	4.83	5.88	6.98
Changes in Accrued Expenses	28.64	8.58	19.77	-4.7	20.68
Changes in Other Operating Activities	-18.14	-14.19	-20.86	-4.07	-3.11
Operating Cash Flow	-302.41	-352.98	-361.82	-292.76	-227.94
Capital Expenditures	-33.84	-11.07	-22.29	-20.43	-37.57
Purchases of Investments	-318.67	-460.77	-205.9	-245.82	-725.21
Proceeds from Sale of Investments	400	428	285.58	522.7	762.91
Payments for Business Acquisitions	-	-52.57	-212.63	-	-
Investing Cash Flow	47.5	-96.41	-155.24	256.46	0.13
Long-Term Debt Issued	-	-	-	-	1
Net Long-Term Debt Issued (Repaid)	-	-	-	-	1
Issuance of Common Stock	307.83	403.52	465.75	192.8	238.27
Repurchase of Common Stock	-7.06	-12.86	-2.8	-2.65	-
Net Common Stock Issued (Repurchased)	300.77	390.66	462.96	190.15	238.27
Financing Cash Flow	300.77	390.66	462.96	190.15	239.27
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1.14	-0.54	-2.74	-	-
Net Cash Flow	47.01	-59.27	-56.84	153.85	11.46
Free Cash Flow	-336.24	-364.05	-384.11	-313.18	-265.52
FCF Margin	-127.61%	-221.88%	-32305.30%	-	-
Free Cash Flow Per Share	-0.94	-1.26	-1.63	-1.97	-1.73
Levered Free Cash Flow	-387.87	-393.01	-429.45	-398.08	-340.29
Unlevered Free Cash Flow	-398.12	-413.13	-442.4	-401.06	-341.74

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q